Study Examining Exenatide Long-Acting Release in Subjects With Type 2 Diabetes
Status:
Completed
Trial end date:
2005-10-01
Target enrollment:
Participant gender:
Summary
Exenatide LAR is a long-acting release formulation of exenatide, which is a twice-daily
dosage form currently under investigation as a potential treatment for people with type 2
diabetes mellitus. This study will assess the safety, tolerability, and pharmacokinetics of
Exenatide LAR administered weekly by subcutaneous injection in people with type 2 diabetes
mellitus.